Chronic Pain Clinical Trial
Official title:
Randomized Trial of Yoga and Physical Therapy Onsite at Opioid Treatment Programs for Patients With Chronic Back Pain and Opioid Use Disorder
This is a pragmatic, open label, randomized controlled trial with 1:1:1 allocation to 12 weeks of: (1) onsite yoga at opioid treatment programs (OTPs), (2) onsite physical therapy (PT) at OTPs, or (3) treatment as usual (TAU). Participants will be 345 individuals with chronic back pain receiving treatment for opioid use disorder (OUD) in community-based OTPs. Through research visits at screening, baseline, and months 1, 2, 3, 6, and 9, the investigators will evaluate pain and opioid use outcomes and implementation outcomes.
Status | Recruiting |
Enrollment | 345 |
Est. completion date | February 2027 |
Est. primary completion date | February 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. age =18 years old 2. English or Spanish proficiency (i.e., be able to participate in study interventions and interviews in English or Spanish) 3. receiving methadone or buprenorphine treatment for OUD in the Montefiore OTP network for at least 12 weeks, with no dose change in 14 days 4. Chronic low or mid back pain, with at least moderate pain severity (score of =4 on the Pain, Enjoyment of Life and General Activity (PEG) Scale 5. Willingness to participate in all study components 6. ability to provide informed consent Exclusion Criteria: 1. severe disabling conditions that could make participation in yoga or PT hazardous 2. acute exacerbation of psychiatric conditions that preclude the ability to participate in the study (e.g., acute mania, active suicidality/homicidality, psychosis) 3. CP related to malignancy 4. yoga practice or PT in the prior 60 days |
Country | Name | City | State |
---|---|---|---|
United States | Montefiore DoSA Wellness Centers | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Albert Einstein College of Medicine | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain Intensity | Brief Pain Inventory (BPI) pain intensity, past 7 days subscale | 6 months | |
Primary | Illicit opioid use | Addiction Severity Index (ASI), days of use in the past 30 days | 6 months | |
Primary | Health-related quality of life | Patient-Reported Outcomes Measurement Information System (PROMIS) Preference (PROPr) scoring system, which uses the respondent's scores for each of 7 PROMIS domains to calculate a health utility index value that represents the general US population's preference for the respondent's current health state: Cognitive Function-Abilities, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Ability to Participate in Social Roles and Activities | Baseline (Week 0), 1 month, 2 months, 3 months, 6 months and 9 months | |
Secondary | Pain Interference | Brief Pain Inventory (BPI): Pain interference will be measured using the BPI sub-scale which produces pain severity and pain interference scores ranging from 0-10, with higher scores indicating worse pain. The subscale consists of 7 items scored on an 11-point response scale ranging from 0 (no interference) to 10 (complete interference). Scores are a sum of all item responses (range 0-70) and provide context for "average pain" over the past week. PEG (Pain, Enjoyment, General Activity) Scale: 3-item scale assessing Pain Intensity and Interference. Individuals rate their pain level, from 0-10, in 3 different areas. The 1st scale asks individuals to rate their pain, on average, over the past week. The 2nd scale asks individuals to rate how pain has interfered with enjoyment of life in the past week. The 3rd scale asks individuals to rate how pain has interfered with general activities. The PEG scale is scored by averaging the three numbers, which monitor changes in pain levels over time | Baseline (Week 0), 1 month, 2 months, 3 months, 6 months and 9 months | |
Secondary | Pain Catastrophizing | Pain Catastrophizing Scale (PCS) short form. The PCS is a 13-item scale, with each item rated on a 5-point scale: 0 (Not at all) to 4 (all the time). The PCS is broken into three subscales which examine rumination, magnification, and helplessness related to pain. A total PCS score of 30 represents clinically relevant level of catastrophizing. | Baseline (Week 0), 1 month, 2 months, 3 months, 6 months and 9 months | |
Secondary | Perceived stress | Assessed using the NIH Toolbox Perceived Stress Fixed Form 18+ | Baseline (Week 0), 3 months, 6 months and 9 months | |
Secondary | Cost effectiveness | Incremental cost-effectiveness ratio (ICER) associated with yoga or PT vs. TAU. The ICER will be calculated by dividing (mean) incremental cost associated with yoga/PT vs TAU by (mean) incremental effectiveness. Cost components will include: costs of intervention delivery, costs of other healthcare services, participant time costs, labor market earnings. The effectiveness measure will be Health Related Quality of Life (HRQoL)measured using a utility score resulting from the PROMIS-Preference (PROPr) scoring system. | 9 month intervention period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|